News articles about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.2147045724245 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- GenMark Diagnostics (GNMK) Raised to “Sell” at BidaskClub (americanbankingnews.com)
- $17.53 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter (americanbankingnews.com)
- Head to Head Comparison: ResMed (RMD) & GenMark Diagnostics (GNMK) (americanbankingnews.com)
- Zacks: Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Post Earnings of -$0.21 Per Share (americanbankingnews.com)
- Blog Exposure – Zimmer Biomet Showcased New Product and Service Innovations at American Academy of Orthopaedic Surgeons Annual Meeting 2018 (finance.yahoo.com)
A number of equities analysts recently weighed in on the stock. BidaskClub upgraded shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. Canaccord Genuity decreased their target price on shares of GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of GenMark Diagnostics in a report on Friday, January 19th. Finally, BTIG Research set a $11.00 target price on shares of GenMark Diagnostics and gave the company a “buy” rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $10.60.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). GenMark Diagnostics had a negative net margin of 117.77% and a negative return on equity of 91.14%. The firm had revenue of $16.02 million for the quarter, compared to analyst estimates of $15.82 million. research analysts anticipate that GenMark Diagnostics will post -0.78 earnings per share for the current year.
In related news, insider Hany Massarany sold 6,584 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $4.37, for a total transaction of $28,772.08. Following the sale, the insider now directly owns 357,190 shares of the company’s stock, valued at approximately $1,560,920.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott Mendel sold 6,275 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $4.17, for a total transaction of $26,166.75. Following the sale, the chief financial officer now directly owns 246,161 shares in the company, valued at $1,026,491.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,164 shares of company stock worth $217,957. 7.50% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/14/genmark-diagnostics-gnmk-receiving-somewhat-positive-press-coverage-study-finds/2028757.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.